{
    "eid": "2-s2.0-85101563160",
    "title": "Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "abiraterone",
        "chemotherapy",
        "docetaxel",
        "enzalutamide",
        "metastatic prostate cancer"
    ],
    "authors": [
        "Fabio Augusto Barros Schutz",
        "Ekaphop Sirachainan",
        "Shanggar Kuppusamy",
        "Nguyen Thi Thai Hoa",
        "Thitiya Dejthevaporn",
        "Badrulhisham Bahadzor",
        "Vu Quang Toan",
        "Phichai Chansriwong",
        "Adlinda Alip",
        "Nguyen Thi Minh Hue",
        "Napa Parinyanitikul",
        "Ai Lian Tan",
        "Vu Dinh Khanh Hoang",
        "Piyawan Tienchaiananda",
        "Sai Naga Deepak Chinchapattanam",
        "Amit Garg"
    ],
    "citedby-count": 1,
    "ref-count": 64,
    "ref-list": [
        "Developing a checklist: consensus via a modified Delphi technique",
        "Development of an international undergraduate curriculum for delirium using a modified Delphi process",
        "The Delphi technique: myths and realities",
        "Consensus statements for management of Barrett\u2019s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process",
        "Using the Dephi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma",
        "Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland",
        "Consensus development methods, and their use in clinical guideline development",
        "Development of content-valid technical skill assessment instruments for athletic taping skills",
        "Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task",
        "A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups",
        "Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941",
        "Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion [published correction appears in Nat Clin Pract Urol2009 Mar;6(3):173]",
        "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer",
        "STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial",
        "Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer",
        "STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy",
        "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial",
        "Prognostic value of the Gleason score in prostate cancer",
        "Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiarm, multistage randomized controlled trial",
        "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial",
        "Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial",
        "Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis",
        "Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol. 2020 Mar;31(3):442]",
        "Recent trends in the management of advanced prostate cancer",
        "Abiraterone in metastatic prostate cancer without previous chemotherapy",
        "A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-na\u00efve patients with mCRPC in China, Malaysia, Thailand and Russia",
        "Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer",
        "Management of metastatic castration-resistant prostate cancer: insights from urology experts in Thailand",
        "Overall survival by race in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide",
        "Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)",
        "The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer",
        "Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology",
        "Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: Results of an oncology EMR analysis",
        "Population pharmacokinetic analysis of abiraterone in chemotherapy- na\u00efve and docetaxel-treated patients with metastatic castration-resistant prostate cancer",
        "Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer",
        "Low-fat abiraterone food effect is of little consequence",
        "NF-\u03baB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants",
        "Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? The Istituto Nazionale dei Tumori (INT) Experience",
        "Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study",
        "AR-V7 and treatment selection in advanced prostate cancer: are we there yet?",
        "Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations",
        "Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment",
        "Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers",
        "Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol",
        "Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-na\u00efve prostate cancer: a systematic review and network meta-analysis",
        "What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis",
        "Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation",
        "Enzalutamide with standard first-line therapy in metastatic prostate cancer",
        "Apalutamide for metastatic, castration-sensitive prostate cancer",
        "ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)",
        "Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel",
        "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study",
        "Increased survival with enzalutamide in prostate cancer after chemotherapy",
        "Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide",
        "Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
        "Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer",
        "Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)",
        "Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hyderabad",
            "@id": "60017484",
            "affilname": "Dr. Reddy's Laboratories Ltd. India",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017484",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60013665",
            "affilname": "University of Malaya Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": null,
            "@id": "60103837",
            "affilname": "Hospital Pulau Pinang",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60103837",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Ho Chi Minh City",
            "@id": "60071389",
            "affilname": "Cho Ray Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071389",
            "affiliation-country": "Viet Nam"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005255",
            "affilname": "Rajavithi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005255",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bandar Sunway",
            "@id": "121444563",
            "affilname": "Sunway Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121444563",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Ho Chi Minh City",
            "@id": "107981430",
            "affilname": "Ho Chi Minh City Oncology Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/107981430",
            "affiliation-country": "Viet Nam"
        },
        {
            "affiliation-city": "Hanoi",
            "@id": "100787418",
            "affilname": "National Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100787418",
            "affiliation-country": "Viet Nam"
        }
    ],
    "funding": [
        "Dr Reddy\u2019s Laboratories Ltd."
    ]
}